FDA (Image: AP)
FDA to Lexicon: Yeah, that's still gonna be a no from us
Lexicon’s last hopes for a quick resurrection of its Type 1 diabetes drug in the US have been quashed.
The Texas-based biotech announced that the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
